The stock price of losing loss of losing assets of green biochemical high premiums is staged in four consecutive boards

Lukang Biochemical (002868) has recently announced that because of its optimistic development prospects for the photovoltaic glue film industry, the company plans to acquire 100%equity of Jiangxi Weike. Affected by this news, the company's stock price "one word" daily limit for four consecutive trading days. According to estimates, Jiangxi Weike's estimates will reach 100 million yuan, with a premium rate of about 632%. However, financial data shows that the company's performance in the first four months of this year was lost.

Lost asset performance of the target

On August 1st, Lukang Biochemical announced that it was planned to acquire 100%equity of Jiangxi Weike to cut into the photovoltaic industry and achieve cross -border development. In this regard, the company said: "Because of the optimistic company Jiangxi Weike and the photovoltaic glue film industry in the future development prospects, the estimated valuation of assets is 100 million yuan." According to the data, Jiangxi Weike is mainly engaged in thin film composite materials and photovoltaic facilities R & D, production and sales of components.

However, financial data shows that from January to April 2022, Jiangxi Weike realized operating income of approximately 19.905 million yuan and 18.17 million yuan, respectively; the corresponding net profit was approximately -66.37 million yuan and -68.863 million yuan, respectively.

As the acquisition party, Lukang Biochemical is a company focusing on the development, production and sales of veterinary drugs. Its business scope covers multiple fields such as pre -pre -pre -pre -pre -pre -pre -pre -pre -hypopotors, beasts, and food preservatives. Products, sulfate sticky products, nanomycin food preservatives, etc. Compared with the two, Lukang Biochemical is a cross -border acquisition.

In terms of performance, Lukang Biochemical achieved a net profit of -26.04 million yuan in 2021. In the first quarter of this year, the company achieved a net profit of -89.14 million yuan. In addition, Lukang Biochemical estimates that the company achieved a net profit loss of 35 million yuan to 43 million yuan in the first half of this year. Some reasons for the pre -losing loss are that the company's veterinary drug fundraising project and the construction of thermal power joint projects have been completed and depreciated in the second quarter. Due to the production capacity climbing and other reasons, the corresponding cost of the veterinary drug fundraising project and the thermal power joint project is relatively high. , The trial product of the veterinary drug fundraising project is prepared for inventory price decline.

After the plan was released

During the market, affected by the news of cross -border acquisitions, from August 1st to August 4th, Lukang Biochemical's stock price daily limit of four consecutive trading days, touching the standard fluctuation standards of stock transactions.

"The above transactions must pass the audit evaluation of the intermediary agency and the review of the Shenzhen Stock Exchange. The second interim shareholders meeting, which was originally scheduled to be held on August 16, 2022. "

Regarding the evaluation of the underlying assets, Jiangxi Weike's assets were estimated at 100 million yuan, and the evaluation premium rate was 632%. It should be mentioned that in this announcement, if the final transaction price is less than 95 million yuan, the transaction party has the right to terminate the asset acquisition agreement. In the face of the above situation, the Shenzhen Stock Exchange asked the company: "The purchase of the target asset performance loss and the high asset -liability ratio will help the company's operating quality, whether there is a situation in which the hot spot speculation is catered to the stock price."

Financial data shows that Jiangxi Weike's asset-liability ratio reached 92%from January to April 2022.

In addition, it should be mentioned that the transaction that plans to acquire 100%equity of Jiangxi Weike's 100%equity of Jiangxi Weiko is based on the company's shareholders of Asia, Fujie Pingtan, and the Beijing Kangmin Agreement. The premise of 100%equity of Fujian Pond. After the transfer of the above shares, Holi Asia holds 3.083 million shares of the company, accounting for 2%of the company's total share capital. Fujie Pingtan and Beijing Kangmin no longer hold company shares directly.

Reporter Zhang Yan

- END -